Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Glucose: a continuous risk factor for cardiovascular disease

H C Gerstein1

  • 1Department of Medicine, McMaster University, Preventive Cardiology and Therapeutics Programme, Hamilton Civics Hospital Research Centre, Ontario, Canada.

Diabetic Medicine : a Journal of the British Diabetic Association
|August 1, 1997
PubMed
Summary

High blood glucose levels increase the risk of diabetes complications like eye and kidney disease. This elevated glucose is also a continuous risk factor for cardiovascular disease (CVD) in all individuals.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

What accounts for ethnic differences in newborn skinfold thickness comparing South Asians and White Caucasians? Findings from the START and FAMILY Birth Cohorts.

International journal of obesity (2005)·2015
Same author

Lack of association between type 2 diabetes and major depression: epidemiologic and genetic evidence in a multiethnic population.

Translational psychiatry·2015
Same author

Impact of rosiglitazone on body composition, hepatic fat, fatty acids, adipokines and glucose in persons with impaired fasting glucose or impaired glucose tolerance: a sub-study of the DREAM trial.

Diabetic medicine : a journal of the British Diabetic Association·2014
Same author

Cost implications of the use of basal insulin glargine in people with early dysglycemia: the ORIGIN trial.

Journal of diabetes and its complications·2014
Same author

Hyperglycaemia is associated with impaired vasa vasorum neovascularization and accelerated atherosclerosis in apolipoprotein-E deficient mice.

Atherosclerosis·2013
Same author

Increased cardiovascular risk after pre-eclampsia in women with dysglycaemia.

Diabetic medicine : a journal of the British Diabetic Association·2012

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Cardiovascular Epidemiology

Background:

  • Diabetes mellitus is defined by glucose levels associated with high risk of microvascular complications.
  • Elevated glucose levels are a continuous risk factor for diabetic complications, including eye, kidney, and neuronal diseases.
  • Therapeutic interventions lowering glucose can reduce the risk of these complications.

Purpose of the Study:

  • To examine the relationship between plasma glucose concentrations and cardiovascular disease (CVD).
  • To determine if the association between glucose and CVD extends below diabetes diagnostic thresholds.
  • To understand the implications of glucose as a risk factor for CVD in the general population.

Main Methods:

  • Review of epidemiological evidence on plasma glucose concentrations and CVD risk.

Related Experiment Videos

  • Analysis of the continuous relationship between glucose levels and cardiovascular outcomes.
  • Comparison of glucose-CVD relationship with established risk factors like cholesterol and blood pressure.

    • Main Results:

    • Plasma glucose in the diabetic range is a continuous risk factor for CVD.
    • The glucose-CVD relationship extends to levels below those defined for diabetes and impaired glucose tolerance.
    • This continuous association is observed in the general population, not solely in individuals with diagnosed metabolic conditions.

    Conclusions:

    • Elevated plasma glucose is a continuous risk factor for cardiovascular disease across a spectrum of glucose levels.
    • The underlying mechanism may involve direct glucose effects or shared metabolic abnormalities.
    • Further clinical trials are needed to ascertain if glucose-lowering interventions reduce CVD risk.